163 related articles for article (PubMed ID: 25109957)
1. Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer.
Sale MJ; Cook SJ
Biochem Soc Trans; 2014 Aug; 42(4):776-83. PubMed ID: 25109957
[TBL] [Abstract][Full Text] [Related]
2. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
Mandal R; Becker S; Strebhardt K
Oncogene; 2016 May; 35(20):2547-61. PubMed ID: 26364606
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ
Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312
[TBL] [Abstract][Full Text] [Related]
4. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
[TBL] [Abstract][Full Text] [Related]
5. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798
[TBL] [Abstract][Full Text] [Related]
6. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.
Caunt CJ; Sale MJ; Smith PD; Cook SJ
Nat Rev Cancer; 2015 Oct; 15(10):577-92. PubMed ID: 26399658
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.
Daouti S; Wang H; Li WH; Higgins B; Kolinsky K; Packman K; Specian A; Kong N; Huby N; Wen Y; Xiang Q; Podlaski FJ; He Y; Fotouhi N; Heimbrook D; Niu H
Cancer Res; 2009 Mar; 69(5):1924-32. PubMed ID: 19244124
[TBL] [Abstract][Full Text] [Related]
8. MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.
Wu PK; Park JI
Semin Oncol; 2015 Dec; 42(6):849-62. PubMed ID: 26615130
[TBL] [Abstract][Full Text] [Related]
9. MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF
Sale MJ; Balmanno K; Saxena J; Ozono E; Wojdyla K; McIntyre RE; Gilley R; Woroniuk A; Howarth KD; Hughes G; Dry JR; Arends MJ; Caro P; Oxley D; Ashton S; Adams DJ; Saez-Rodriguez J; Smith PD; Cook SJ
Nat Commun; 2019 May; 10(1):2030. PubMed ID: 31048689
[TBL] [Abstract][Full Text] [Related]
10. Ras/mitogen-activated protein kinase (MAPK) signaling modulates protein stability and cell surface expression of scavenger receptor SR-BI.
Wood P; Mulay V; Darabi M; Chan KC; Heeren J; Pol A; Lambert G; Rye KA; Enrich C; Grewal T
J Biol Chem; 2011 Jul; 286(26):23077-92. PubMed ID: 21525007
[TBL] [Abstract][Full Text] [Related]
11. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
Hong SK; Wu PK; Karkhanis M; Park JI
Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
[TBL] [Abstract][Full Text] [Related]
12. That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.
Sale MJ; Cook SJ
Br J Pharmacol; 2013 Aug; 169(8):1708-22. PubMed ID: 23647573
[TBL] [Abstract][Full Text] [Related]
13. Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.
Little AS; Balmanno K; Sale MJ; Smith PD; Cook SJ
Biochem Soc Trans; 2012 Feb; 40(1):73-8. PubMed ID: 22260668
[TBL] [Abstract][Full Text] [Related]
14. ERK1/2 activation mediated by the nutlin‑3‑induced mitochondrial translocation of p53.
Lee SY; Shin SJ; Kim HS
Int J Oncol; 2013 Mar; 42(3):1027-35. PubMed ID: 23314357
[TBL] [Abstract][Full Text] [Related]
15. Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer.
Wang C; Wang H; Zheng C; Liu Z; Gao X; Xu F; Niu Y; Zhang L; Xu P
Eur J Med Chem; 2021 Jun; 218():113386. PubMed ID: 33774345
[TBL] [Abstract][Full Text] [Related]
16. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
17. Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.
Hirschi B; Gallmeier E; Ziesch A; Marschall M; Kolligs FT
Mol Cancer; 2014 May; 13():122. PubMed ID: 24885690
[TBL] [Abstract][Full Text] [Related]
18. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1.
Shibazaki S; Yu Z; Nishio S; Tian X; Thomson RB; Mitobe M; Louvi A; Velazquez H; Ishibe S; Cantley LG; Igarashi P; Somlo S
Hum Mol Genet; 2008 Jun; 17(11):1505-16. PubMed ID: 18263604
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation.
Hoang VT; Matossian MD; La J; Hoang K; Ucar DA; Elliott S; Burks HE; Wright TD; Patel S; Bhatt A; Phamduy T; Chrisey D; Buechlein A; Rusch DB; Nephew KP; Anbalagan M; Rowan B; Cavanaugh JE; Flaherty PT; Miele L; Collins-Burow BM; Burow ME
J Cell Biochem; 2021 Aug; 122(8):835-850. PubMed ID: 33876843
[TBL] [Abstract][Full Text] [Related]
20. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
